These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12542480)

  • 1. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.
    Abildgaard N; Brixen K; Kristensen JE; Eriksen EF; Nielsen JL; Heickendorff L
    Br J Haematol; 2003 Jan; 120(2):235-42. PubMed ID: 12542480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.
    Jakob C; Zavrski I; Heider U; Brux B; Eucker J; Langelotz C; Sinha P; Possinger K; Sezer O
    Eur J Haematol; 2002 Jul; 69(1):37-42. PubMed ID: 12270060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma.
    Abildgaard N; Glerup H; Rungby J; Bendix-Hansen K; Kassem M; Brixen K; Heickendorff L; Nielsen JL; Eriksen EF
    Eur J Haematol; 2000 Feb; 64(2):121-9. PubMed ID: 10997332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios.
    Carlson K; Larsson A; Simonsson B; Turesson I; Westin J; Ljunghall S
    Eur J Haematol; 1999 May; 62(5):300-6. PubMed ID: 10359057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma.
    Abildgaard N; Brixen K; Eriksen EF; Kristensen JE; Nielsen JL; Heickendorff L
    Haematologica; 2004 May; 89(5):567-77. PubMed ID: 15136220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
    Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
    Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.
    Jakob C; Zavrski I; Heider U; Bollow M; Schulz CO; Fleissner C; Eucker J; Michael R; Hamm B; Possinger K; Sezer O
    Clin Cancer Res; 2003 Aug; 9(8):3047-51. PubMed ID: 12912955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.
    Elomaa I; Virkkunen P; Risteli L; Risteli J
    Br J Cancer; 1992 Aug; 66(2):337-41. PubMed ID: 1503907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of biochemical markers in patients with metabolic bone disorders.
    Hoshino H; Kushida K; Takahashi M; Kawana K; Denda M; Yamazaki K; Inoue T
    Endocr Res; 1998 Feb; 24(1):55-64. PubMed ID: 9553754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
    Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
    J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic validity of bone metabolic markers for bone metastasis.
    Miura H; Yamamoto I; Takada M; Kigami Y; Ohta T; Yuu I; Hamanaka Y; Matsushita R; Morita R
    Endocr J; 1997 Oct; 44(5):751-7. PubMed ID: 9466334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.